Zemene Yiglet

Zemene Yiglet

Auto-generated profile, based on publicly available information

Zemene Yiglet

University of Gondar

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2026 in Psychiatry Research
Verified
Journal Article
Closed access
ZYZemene Yiglet
Zemene Yiglet
GKGetasew Kibralew
Getasew Kibralew
HTHilina Tadesse
Hilina Tadesse
WMWorknew Molla
Worknew Molla
YWYeneneh Workie
Yeneneh Workie
MKMulualem Kelebie
Mulualem Kelebie

23 September 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
ZYZemene Yiglet
Zemene Yiglet
GDGoshu Nenko Dukele
Goshu Nenko Dukele
STSeblewongel Tinsea
Seblewongel Tinsea
DGDaniel Ayelegne Gebeyehu
Daniel Ayelegne Gebeyehu
DADawed Ali
Dawed Ali
TGTesfaw Getachew
Tesfaw Getachew
Objective: To determine the prevalence and patterns of aggressive behaviour and identify factors associated with aggressive behaviour among patients with severe mental illness (SMI) attending a tertiary hospital in Northwest Ethiopia in 2025. Design: Institution-based cross-sectional study. Setting: University of Gondar Comprehensive Specialised Hospital, Northwest Ethiopia, conducted from 1 to 30 March 2025. Participants: A total of 423 patients with SMI were selected using a systematic random sampling technique. Outcome measures: Data were collected using interviewer-administered questionnaires and medical record review. Aggressive behaviour was assessed using the Modified Overt Aggression Scale (MOAS). Sociodemographic, clinical, substance use, medication adherence and psychosocial characteristics were assessed using standardised instruments and medical records. Adjusted ORs (AORs) with 95% CIs were estimated, and statistical significance was declared at p<0.05. Results: The prevalence of aggressive behaviour was 32.2% (95% CI 28.0% to 36.9%). Verbal aggression was the most common subtype (25.5%), whereas auto-aggression was the least common (12.4%). Poor medication adherence (AOR = 3.31; 95% CI 1.24 to 8.86), current substance use (AOR = 7.31; 95% CI 2.41 to 22.10), previous history of aggression (AOR = 2.82; 95% CI 1.03 to 7.74), moderate illness severity (AOR = 2.59; 95% CI 1.19 to 5.66) and severe illness severity (AOR = 4.71; 95% CI 1.12 to 19.78) were independently associated with aggressive behaviour. Conclusion: One-third of patients with SMI exhibited aggressive behaviour. Poor medication adherence, current substance use, previous history of aggression and severe illness severity were independently associated with aggressive behaviour. Routine assessment of aggression risk and interventions targeting medication adherence, substance use and illness severity may help reduce aggressive behaviour among patients with SMI.

19 October 2026 in Cambridge Prisms: Global Mental Health
Verified
Journal Article
Open access
PDF file
ZYZemene Yiglet
Zemene Yiglet
YWYeneneh Workie
Yeneneh Workie
GKGetasew Kibralew
Getasew Kibralew
HTHilina Tadesse
Hilina Tadesse
MAMulat Awoke
Mulat Awoke
MKMulualem Kelebie
Mulualem Kelebie
Severe mental illnesses (SMIs), including schizophrenia, bipolar disorder and major depressive disorder with psychotic features or severe functional impairment, are chronic psychiatric disorders associated with substantial disability, impaired functioning and premature mortality. Relapse, the recurrence or worsening of psychiatric symptoms after a period of remission, is a common feature of these disorders and contributes to repeated hospitalization, poor functional outcomes and increased healthcare utilization. Despite its clinical and public health importance, evidence on the lifetime occurrence of relapse and its associated factors remains limited in sub-Saharan Africa, particularly in Ethiopia. Therefore, this study aimed to determine the lifetime prevalence of relapse and identify factors associated with relapse among patients with SMI receiving outpatient psychiatric care in Northwest Ethiopia. An institution-based cross-sectional study was conducted among patients with SMI at the University of Gondar Hospital, Northwest Ethiopia, from April 10 to May 24, 2025. A total of 535 patients with SMI were included using systematic random sampling. Lifetime relapse was assessed using a semistructured interviewer-administered questionnaire supported by medical record review. Data on sociodemographic, clinical, treatment-related and psychosocial characteristics were collected. Binary logistic regression analysis was performed to identify factors associated with lifetime relapse. Variables with a p -value <0.20 in the bivariable analysis were entered into the multivariable model, and statistical significance was declared at p < 0.05. The lifetime prevalence of relapse was 61.5% (95% CI: 57.0%–66.0%). In the multivariable binary logistic regression analysis, lifetime relapse was significantly associated with unemployment (adjusted odds ratio [AOR] = 1.65; 95% CI: 1.07–2.55), bipolar disorder (AOR = 3.71; 95% CI: 1.92–7.19), schizophrenia (AOR = 2.73; 95% CI: 1.68–4.46), previous psychiatric hospitalization (AOR = 3.62; 95% CI: 2.26–5.80), two or more prior psychiatric admissions (AOR = 2.32; 95% CI: 1.27–4.23), illness duration of more than 10 years (AOR = 2.04; 95% CI: 1.07–3.88), comorbid medical illness (AOR = 2.41; 95% CI: 1.27–4.58) and experiencing one or two (AOR = 1.81; 95% CI: 1.03–3.18) or three or more stressful life events (AOR = 2.16; 95% CI: 1.16–4.05). Lifetime relapse affected nearly two-thirds of patients with SMI. Factors associated with relapse included unemployment, bipolar disorder, schizophrenia, previous psychiatric hospitalization, multiple prior admissions, longer illness duration, comorbid medical illness and stressful life events. These findings highlight the importance of targeted clinical monitoring and interventions for individuals with characteristics associated with relapse, alongside strengthened continuity of care and integrated mental health services to support relapse prevention and improve long-term outcomes.